Impact of rheumatoid arthritis disease activity test on clinical practice

John W Peabody, Vibeke Strand, Riti Shimkhada, Rachel Lee, David Chernoff, John W Peabody, Vibeke Strand, Riti Shimkhada, Rachel Lee, David Chernoff

Abstract

Background: Variability exists in the assessment of disease activity in rheumatoid arthritis (RA) patients that may affect quality of care.

Objectives: To measure the impact on quality of care of a Multi-Biomarker Disease Activity (MBDA) test that quantitatively assesses RA disease activity.

Methods: Board-certified rheumatologists without prior experience with the MBDA test (N = 81) were randomized into an intervention or control group as part of a longitudinal randomized-control study. All physicians were asked to care for three simulated RA patients, using Clinical Performance and Value (CPV™) vignettes, in a before and after design. CPV™ vignettes have been validated to assess the quality of clinical practice and identify variation in care. The vignettes covered all domains of a regular patient visit; scores were determined as a percentage of explicit predefined criteria completed. Three vignettes, representing typical RA cases, were administered each round. In the first round, no physician received information about the MBDA test. In the second round, only physicians in the intervention group were given educational materials about the test and hypothetical test results for each of the simulated patients. The outcome measures were the overall quality of care, disease assessment and treatment.

Results: The overall quality scores in the intervention group improved by 3 percent (p = 0.02) post-intervention compared with baseline, versus no change in the control group. The greatest benefit in the intervention group was to the quality of disease activity assessment and treatment decisions, which improved by 12 percent (p<0.01) compared with no significant change in the control group. The intervention was associated with more appropriate use of biologic and/or combination DMARDs in the co-morbidity case type (p<0.01).

Conclusions: Based on these results, use of the MBDA test improved the assessment and treatment decisions for simulated cases of RA and may prove useful for rheumatologists in clinical practice.

Conflict of interest statement

Competing Interests: VS and DC are paid consultants of Crescendo Biosciences. QURE Healthcare was contracted by Crescendo to conduct this study and analysis. Crescendo Bioscience, Inc. was the commercial funder. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1. Flow diagram of sample selection.
Figure 1. Flow diagram of sample selection.

References

    1. Sacks JJ, Luo YH, Helmick CG (2010) Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. Arthritis Care Res (Hoboken) 62: 460–4.
    1. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, et al. (2001) ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104: 2118–50.
    1. Majithia V, Geraci SA (2007) Rheumatoid arthritis: diagnosis and management. Am J Med 120: 936–9.
    1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62: 2569–81.
    1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631–637.
    1. Smolen JS, Landewe R, Breedveld FC, Dougados M, Gaujoux-Viala C, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964–75.
    1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, et al. (2012) Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64: 625–639.
    1. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, et al. (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 64: 640–7.
    1. Studenic P, Rader H, Smolen JS, Aletaha D (2012) Arthritis Rheum Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 64: 2814–23.
    1. Masri KR, Shaver KS, Shadouri SH (2012) Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice. J Rheumatol (39): 1139–45.
    1. Beresniak A, Russell AS, Haraoui B, Bessette L, Bombardier C, et al. (2007) Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 34: 2193–200.
    1. Bykerk VP, Schieir O, Akhavan P, Hazlewood GS, Cheng CK, et al. (2011) Emerging Issues in Pharmacological Management of Rheumatoid Arthritis: Results of a National Needs Assessment Survey Identifying Practice Variations for the Development of Canadian Rheumatology Association Clinical Practice Recommendations. J Rheumatol 39: 1555–8.
    1. Lacaille D, Anis AH, Guh DP, Esdaile JM (2005) Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 53: 241–8.
    1. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, et al. (2000) Quality of care for patients with rheumatoid arthritis. JAMA 284: 984–92.
    1. Peabody JW, Strand V, Chernoff D, Ta HM (2012) Evaluation of Clinical Performance and Variation Among Three Types of Patients with Rheumatoid Arthritis: Opportunities to Raise Quality and Lower Costs. ISPOR 17th Annual International Meeting; Washington D.C.
    1. Jiang Y, Nishikawa RM, Schmidt RA, Toledano AY, Doi K (2001) Potential of computer-aided diagnosis to reduce variability in radiologists' interpretations of mammograms depicting microcalcifications. Radiology 220: 787–94.
    1. Butcher L (2009) Health plans and providers struggle to fix payment system. Manag Care 18: 30–3.
    1. Panella M, Marchisio S, Di Stanislao F (2003) Reducing clinical variations with clinical pathways: do pathways work? Int J Qual Health Care 15: 509–21.
    1. Farheen K, Agarwal SK (2011) Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manag Care Pharm 17: S09–13.
    1. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, et al. (2012) Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal 70: 415–424.
    1. Zhao X, Qureshi F, Eastman PS, Manning WC, Alexander C, et al. (2012) Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. J Immunol Methods 30: 72–80.
    1. Bakker MF, Cavet G, Jacobs JW, Bijlsma JW, Haney DJ, et al. (2012) Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 71: 1692–1697.
    1. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, et al. (2012) Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 64: 1794–803.
    1. van der Helm-van Mil AH, Knevel R, Cavet G, Huizinga TW, Haney DJ (2012) An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology: in press.
    1. Graf J, Scherzer R, Grunfeld C, Imboden J (2009) Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 4: e6242.
    1. Wolfe F (2009) The many myths of erythrocyte sedimentation rate and C-reactive protein. J Rheumatol 36: 1568–69.
    1. Dresselhaus TR, Peabody JW, Luck J, Bertenthal D (2004) An evaluation of vignettes for predicting variation in the quality of preventive care. J Gen Intern Med 19: 1013–8.
    1. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M (2000) Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA 283: 1715–22.
    1. Peabody JW, Luck J, Glassman P, Jain S, Hansen J, et al. (2004) Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med 141: 771–80.
    1. Fox MG, Stephens T, Jarjour WN, Anderson MW, Kimpel DL (2012) Contrast-enhanced magnetic resonance imaging positively impacts the management of some patients with rheumatoid arthritis or suspected RA. J Clin Rheumatol. 18: 15–22.
    1. Wennberg DE (1998) Variation in the delivery of health care: the stakes are high. Ann Intern Med 128: 866–8.
    1. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, et al. (2009) Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 151: 206–9.
    1. Peabody JW, Liu A (2007) A cross-national comparison of the quality of clinical care using vignettes. Health Policy Plan 22: 294–302.
    1. Solon O, Woo K, Quimbo SA, Shimkhada R, Florentino J, et al. (2009) A novel method for measuring health care system performance: experience from QIDS in the Philippines. Health Policy Plan 24: 167–74.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren